Indication

FGFR3 Gene Amplification

1 clinical trial

1 product

Clinical trial

A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Status: Active (not recruiting), Estimated PCD: 2022-05-13

Product